We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sol Gel Technologies Ltd | NASDAQ:SLGL | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.0286 | 3.32% | 0.8896 | 0.3498 | 0.8716 | 0.8999 | 0.86 | 0.86 | 3,068 | 00:58:31 |
From Apr 2021 to Apr 2024
By Colin Kellaher
Sol-Gel Technologies Ltd. on Tuesday said the U.S. Food and Drug Administration approved Twyneo, the company's first proprietary drug product, for the treatment of acne vulgaris in patients ages nine and older.
The Ness Ziona, Israel, dermatology company, which earlier this year signed a licensing agreement with privately held Galderma to commercialize Twyneo in the U.S., said it expects to receive a regulatory milestone payment in conjunction with the approval.
Sol-Gel noted it retains the option to regain U.S. commercialization rights five years after the first U.S. sales, adding that Twyneo is patent-protected until 2038.
Trading in shares of Sol-Gel, which closed Monday at $12.11, was halted premarket on Tuesday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
July 27, 2021 09:44 ET (13:44 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Sol Gel Technologies Chart |
1 Month Sol Gel Technologies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
